Tesamorelin

What is Tesamorelin, and is it FDA-Approved?

Tesamorelin is a synthetic GHRH analog developed by Theratechnologies and marketed as the Egrifta formulation. It binds GHRH receptors on anterior pituitary somatotrophs, stimulating pulsatile growth hormone release and downstream IGF-1 activity. Its FDA-approved indication is the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Tesamorelin is FDA-approved for reducing excess fat in the stomach area in HIV-infected adults with lipodystrophy. However, its approved use should be clearly distinguished from general weight-loss, bodybuilding, anti-aging, or broad GH-optimization protocols. The approved label explicitly states that Tesamorelin is not indicated for weight-loss management.

Within the GHRH analog class, this active approval gives Tesamorelin a unique regulatory standing. Sermorelin has historical FDA approval but is no longer marketed as an approved product, and CJC-1295 has no approved indication. Tesamorelin is the benchmark for any regulatory-anchored discussion of GHRH analogs.

How Tesamorelin Works: GHRH Analog Mechanism

Tesamorelin binds GHRH receptors on pituitary somatotroph cells, stimulating pulsatile GH secretion. GH then acts on peripheral tissues and the liver to increase IGF-1 activity, supporting the lipolytic and metabolic effects that underlie its approved indication.

Key mechanistic features include the following:

• Selective visceral fat reduction: In the approved indication, Tesamorelin reduces visceral (intra-abdominal) adipose tissue without a significant effect on subcutaneous fat. This is a clinically meaningful distinction from general weight-loss agents.
• Pulsatility preservation: Tesamorelin preserves pituitary-mediated GH pulsatility and hypothalamic feedback regulation, rather than replacing GH directly with exogenous synthetic growth hormone.
• Half-life: Approximately 26 minutes, which is longer than Sermorelin’s commonly referenced 10–20 minute range but far shorter than CJC-1295 with DAC. This supports once-daily Tesamorelin injection rather than weekly dosing.

Tesamorelin Benefits and Before and After

Tesamorelin’s benefits are best anchored in its strongest evidence base: visceral fat reduction in HIV-associated lipodystrophy.

• Visceral fat reduction (approved indication): In a randomized, placebo-controlled trial by Falutz et al., published in 2010, Tesamorelin 2 mg, administered subcutaneously once daily, significantly reduced visceral adipose tissue compared with placebo over 26 weeks; patients who continued therapy achieved an approximately 18% reduction in visceral adipose tissue.
• GH and IGF-1 elevation: Downstream effects of pituitary GH stimulation support body composition changes in the approved population.
• Body composition and weight loss framing: Visceral fat reduction is clinically distinct from total body weight loss. Practitioners should clarify this distinction for patients and avoid presenting Tesamorelin as a general weight-loss medication.
• Off-label body composition and GH optimization: Tesamorelin dosage for bodybuilding and broader GH optimization protocols is discussed in practitioner settings, typically framed as 1–2 mg daily subcutaneously. These applications are extrapolated from approved indication data and GH/IGF-1 physiology, not supported by dedicated bodybuilding RCTs. All off-label use should be managed by a qualified care team with appropriate monitoring.

Tesamorelin Dosage and Injection

• Approved dosage (Egrifta): Earlier labeling references 2 mg subcutaneously once daily. Newer EGRIFTA WR labeling specifies 1.28 mg subcutaneously once daily from the weekly-reconstituted vial system. EGRIFTA WR and EGRIFTA SV are not substitutable. Practitioners should verify the current product label at the time of any protocol discussion, as formulation-specific dosing continues to evolve.
• Injection site: The abdomen is identified in the current labeling. Sites should be rotated, and injections should not be placed into scar tissue, bruised areas, or the navel. Product-specific instructions for needles and syringes, reconstitution, and disposal should be followed exactly.
• Off-label dosing: Practitioner-reported protocols for bodybuilding or GH optimization typically cite 1–2 mg daily subcutaneously. This should not be presented as an FDA-validated protocol. Off-label use requires an individualized professional assessment, IGF-1 and glucose monitoring, and a full contraindication review.
• Storage: EGRIFTA WR is supplied as lyophilized powder with diluent; post-reconstitution, refrigerate at 2–8°C, protect from light, and follow product-specific stability instructions.

Is Tesamorelin Safe? What Are Its Side Effects?

Tesamorelin has extensive Phase 3 clinical trial safety data from the approved indication, but safety depends on patient selection, indication, formulation, and monitoring. Key considerations include:

• Common side effects: Injection-site reactions (erythema, pruritus, pain, irritation, bruising) are most frequently reported.
• GH-mediated effects: Fluid retention, arthralgia, peripheral edema, and carpal tunnel-type symptoms may occur and are dose-dependent.
• IGF-1 monitoring: Elevated IGF-1 levels require regular monitoring, particularly for off-label GH optimization or body composition protocols, where the approved indication’s risk-benefit data may not apply.
• Glucose monitoring: GH elevation can worsen insulin resistance; blood glucose should be monitored in patients with pre-existing metabolic risk or abnormal glucose status.
• FDA labeling warnings: Include malignancy risk, hypersensitivity, and contraindications. Off-label use requires added caution because the evidence base and risk-benefit profile differ from those in the approved HIV lipodystrophy population.

Legal Status of Tesamorelin

As of June 2026, Tesamorelin’s regulatory status by jurisdiction is as follows:

• United States: FDA-approved as Egrifta and EGRIFTA WR/SV for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. This is a prescription-only indication. Off-label use occurs at the prescriber’s discretion but must remain clearly distinguished from the approved indication. Compounded Tesamorelin is not automatically equivalent to Egrifta or EGRIFTA WR. Practitioners should consult current FDA guidance directly regarding 503A and 503B compounding frameworks and bulk-substance status before drawing conclusions about compounded availability.
• Australia: Tesamorelin is not widely marketed as a TGA-approved pharmaceutical. Practitioners should verify current TGA classification, importation rules, and prescribing requirements before any patient-facing discussion.
• WADA: GHRH analogs, including Tesamorelin, are prohibited under the S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics category. Competitive athletes and sports medicine professionals must verify the current WADA Prohibited List before discussing any GH-axis peptide.

Where Can Practitioners Buy Tesamorelin Online?

Practitioners who choose to buy Tesamorelin online should confirm that any supplier serves qualified professionals only and provides documentation supporting a compliant procurement decision. When evaluating how to purchase Tesamorelin from a verified source, practitioners should look for suppliers that provide a certificate of analysis, LOT number traceability, and clear purity documentation for each batch. These are minimum requirements for research-grade procurement and are not optional in a compliant sourcing workflow.

Practitioners who want to order Tesamorelin for licensed research or protocol evaluation can contact Doctor Medica’s staff for guidance and instructions on identifying qualified suppliers and obtaining the supporting documentation needed to make informed sourcing decisions. Doctor Medica connects licensed professionals with research-grade suppliers and does not substitute for jurisdiction-specific regulatory review.

Tesamorelin vs Sermorelin, CJC-1295, and Ipamorelin

Tesamorelin’s FDA approval and visceral fat-specific RCT data give it a distinct position in the GHRH analog landscape that no current alternative can match on regulatory grounds.

Sermorelin

Both Tesamorelin and Sermorelin are GHRH analogs, but they differ in regulatory status, half-life, and evidence base. Practitioners who buy Sermorelin for broader GH-axis optimization and body composition research are working with a compound that has historical, but no current, FDA approval. Tesamorelin has a longer half-life of approximately 26 minutes compared with Sermorelin’s commonly cited 10–20 minutes, as supported by a randomized Phase 3 clinical dataset for the approved indication and an active prescription product label.

When the research or protocol question involves documented visceral fat outcomes or a regulatory anchor point, Tesamorelin is the stronger choice.

CJC-1295

Tesamorelin requires daily subcutaneous administration, while practitioners who buy CJC-1295 for extended GH-axis stimulation are working with a DAC-modified analog designed for a half-life of approximately eight days and once-weekly dosing. Tesamorelin’s advantage is its FDA approval, evidence-based labeling for visceral fat, and activity. CJC-1295 offers dosing convenience but lacks any approved indication.

When regulatory evidence and indication-specific data are the primary evaluation criteria, Tesamorelin is the more defensible choice; when dosing frequency is the priority, CJC-1295 may be preferred in research contexts.

Ipamorelin

Tesamorelin acts through the GHRH receptor in the anterior pituitary, whereas practitioners who buy Ipamorelin for selective GH secretagogue research are working with a ghrelin receptor agonist that triggers GH pulse initiation via a different pathway. Ipamorelin is distinguished by its selectivity — it does not typically elevate cortisol or prolactin, which makes it a commonly discussed pairing in protocols where GH stimulation is the goal and side-effect minimization is a priority.

Tesamorelin provides the GHRH-driven amplitude and pituitary pathway, while Ipamorelin contributes to selective pulse initiation. Any combination rationale should remain practitioner-reported and evidence-qualified. Doctor Medica’s staff can provide additional context on these comparisons and can guide practitioners on sourcing from qualified suppliers.

FAQs

1. What is Tesamorelin?

Tesamorelin is a synthetic GHRH analog marketed as Egrifta and EGRIFTA WR/SV. It stimulates pituitary growth hormone release and downstream IGF-1 activity. Its FDA-approved indication is the reduction of excess visceral abdominal fat in HIV-infected adults with lipodystrophy.

2. Is Tesamorelin FDA-approved?

Yes. Tesamorelin is FDA-approved for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. It is not FDA-approved for general weight loss, bodybuilding, or broad GH optimization protocols.

3. What does Tesamorelin do?

Tesamorelin binds GHRH receptors on anterior pituitary somatotrophs and stimulates pulsatile growth hormone release. This increases downstream IGF-1 activity and drives selective visceral fat reduction in the approved indication for HIV lipodystrophy. Off-label body composition applications should be framed separately from the approved indication.

4. What is the Tesamorelin dosage?

Approved dosage depends on the formulation: earlier Egrifta labeling references 2 mg subcutaneously once daily, while EGRIFTA WR labeling specifies 1.28 mg once daily after weekly reconstitution. Off-label dosing for bodybuilding or GH optimization is practitioner-reported at 1–2 mg daily and is not an FDA-validated protocol. Practitioners should verify the current active product label before applying any dosing framework.

5. Is Tesamorelin safe?

Tesamorelin has extensive safety data from Phase 3 clinical trials for its approved indication. Safety monitoring should include IGF-1 levels, glucose status, injection-site reactions, fluid retention, and malignancy history. Off-label use requires additional caution because the evidence base and risk-benefit profile differ from those in the approved HIV lipodystrophy population.

6. What are the Tesamorelin side effects?

Common Tesamorelin side effects include injection-site redness, itching, pain, irritation, and bruising. GH-mediated effects such as fluid retention, joint pain, peripheral edema, and carpal tunnel-type symptoms may also occur. Glucose changes and elevated IGF-1 require regular monitoring.

7. How does Tesamorelin compare to Sermorelin?

Tesamorelin and Sermorelin are both GHRH analogs, but their regulatory and evidence profiles differ significantly. Tesamorelin is FDA-approved for visceral fat reduction in HIV lipodystrophy and is supported by randomized Phase 3 clinical data for that endpoint. Sermorelin has a historical use in growth hormone deficiency but is not currently marketed as an FDA-approved product.

References

1. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. doi:10.1097/QAI.0b013e3181cbdaff
2. Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; August 2016.
3. Grunfeld C, Dritselis A, Kirkpatrick P. Tesamorelin. Nat Rev Drug Discov. 2011;10(2):95-96. doi:10.1038/nrd3362
4. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. doi:10.1345/aph.1Q629

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.